Frontier Says HIV Therapy Effective in Difficult-to-Treat Patients
July 19, 2021 at 05:19 AM EDT
Nanjing Frontier Biotech announced positive top-line results from a China Phase III trial of its long-acting two-drug therapy for AIDS. In the trial, Frontier's once-weekly Aikening® (albuvirtide) plus lopinavir (LPV) showed it was not inferior to a lopinavir three-drug arm in an Asian population that had failed initial treatment. Two NRTIs were replaced with Aikening® in the combination therapy, which produced rapid and persistent viral suppression. More details.... Share this with colleagues: // //